These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 37197312)

  • 1. A Bayesian decision-theoretic design for simultaneous biomarker-based subgroup selection and efficacy evaluation.
    Wang Z; Wang F; Wang C; Zhang J; Wang H; Shi L; Tang Z; Rosner GL
    Stat Biopharm Res; 2022; 14(4):568-579. PubMed ID: 37197312
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bayesian Two-stage Biomarker-based Adaptive Design for Targeted Therapy Development.
    Gu X; Chen N; Wei C; Liu S; Papadimitrakopoulou VA; Herbst RS; Lee JJ
    Stat Biosci; 2016 Jun; 8(1):99-128. PubMed ID: 27617040
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biomarker-based Bayesian randomized phase II clinical trial design to identify a sensitive patient subpopulation.
    Morita S; Yamamoto H; Sugitani Y
    Stat Med; 2014 Oct; 33(23):4008-16. PubMed ID: 24820639
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IBIS: identify biomarker-based subgroups with a Bayesian enrichment design for targeted combination therapy.
    Chen X; Zhang J; Jiang L; Yan F
    BMC Med Res Methodol; 2023 Mar; 23(1):66. PubMed ID: 36941537
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase III Precision Medicine Clinical Trial Designs That Integrate Treatment and Biomarker Evaluation.
    Polley MC; Korn EL; Freidlin B
    JCO Precis Oncol; 2019; 3():. PubMed ID: 32923845
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An adaptive biomarker basket design in phase II oncology trials.
    Liu S; Takeda K; Rong A
    Pharm Stat; 2023 Jan; 22(1):128-142. PubMed ID: 36163614
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Implementing a decision-theoretic design in clinical trials: why and how?
    Palmer CR; Shahumyan H
    Stat Med; 2007 Nov; 26(27):4939-57. PubMed ID: 17582801
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bayesian decision-theoretic group sequential clinical trial design based on a quadratic loss function: a frequentist evaluation.
    Lewis RJ; Lipsky AM; Berry DA
    Clin Trials; 2007; 4(1):5-14. PubMed ID: 17327241
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Marker Sequential Test (MaST) design.
    Freidlin B; Korn EL; Gray R
    Clin Trials; 2014 Feb; 11(1):19-27. PubMed ID: 24085774
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bayesian Approaches to Subgroup Analysis and Related Adaptive Clinical Trial Designs.
    Nugent C; Guo W; Müller P; Ji Y
    JCO Precis Oncol; 2019; 3():. PubMed ID: 32923858
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bayesian adaptive decision-theoretic designs for multi-arm multi-stage clinical trials.
    Bassi A; Berkhof J; de Jong D; van de Ven PM
    Stat Methods Med Res; 2021 Mar; 30(3):717-730. PubMed ID: 33243087
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biomarker-based Bayesian randomized clinical trial design for identifying a target population.
    Sugitani Y; Morita S; Nakakura A; Yamamoto H
    Stat Med; 2023 Jul; 42(16):2797-2810. PubMed ID: 37078122
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Accelerating clinical development of HIV vaccine strategies: methodological challenges and considerations in constructing an optimised multi-arm phase I/II trial design.
    Richert L; Doussau A; Lelièvre JD; Arnold V; Rieux V; Bouakane A; Lévy Y; Chêne G; Thiébaut R;
    Trials; 2014 Feb; 15():68. PubMed ID: 24571662
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of a multi-arm multi-stage Bayesian design for phase II drug selection trials - an example in hemato-oncology.
    Jacob L; Uvarova M; Boulet S; Begaj I; Chevret S
    BMC Med Res Methodol; 2016 Jun; 16():67. PubMed ID: 27250349
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Bayesian phase I/II biomarker-based design for identifying subgroup-specific optimal dose for immunotherapy.
    Guo B; Zang Y
    Stat Methods Med Res; 2022 Jun; 31(6):1104-1119. PubMed ID: 35191780
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bayesian order constrained adaptive design for phase II clinical trials evaluating subgroup-specific treatment effect.
    Shan M; Guo B; Liu H; Li Q; Zang Y
    Stat Methods Med Res; 2023 May; 32(5):885-894. PubMed ID: 36919375
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimizing subgroup selection in two-stage adaptive enrichment and umbrella designs.
    Ballarini NM; Burnett T; Jaki T; Jennison C; König F; Posch M
    Stat Med; 2021 May; 40(12):2939-2956. PubMed ID: 33783020
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimal predictive probability designs for randomized biomarker-guided oncology trials.
    Zabor EC; Kaizer AM; Pennell NA; Hobbs BP
    Front Oncol; 2022; 12():955056. PubMed ID: 36561534
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An adaptive design for updating the threshold value of a continuous biomarker.
    Spencer AV; Harbron C; Mander A; Wason J; Peers I
    Stat Med; 2016 Nov; 35(27):4909-4923. PubMed ID: 27417407
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.